Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Burwig Susan EOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-102Price:$403.00
-
Mar 14, 2024 (filed on Mar 18, 2024)Insider Name:Keating Ashley M.Ownership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-500Price:--
-
Mar 14, 2024 (filed on Mar 18, 2024)Insider Name:Keating Ashley M.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-250Price:$409.87
-
Mar 14, 2024 (filed on Mar 18, 2024)Insider Name:Keating Ashley M.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:500Price:$84.36
-
Mar 08, 2024 (filed on Mar 08, 2024)Insider Name:Troendle August J.Ownership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-25,000Price:$408.71
-
Mar 08, 2024 (filed on Mar 08, 2024)Insider Name:Medpace Investors, LLCOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-25,000Price:$408.71
-
Mar 07, 2024 (filed on Mar 08, 2024)Insider Name:Troendle August J.Ownership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-75,000Price:$410.74
-
Mar 07, 2024 (filed on Mar 08, 2024)Insider Name:Medpace Investors, LLCOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-75,000Price:$410.74
-
Mar 07, 2024 (filed on Mar 08, 2024)Insider Name:Keating Ashley M.Ownership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-472Price:--
-
Mar 07, 2024 (filed on Mar 08, 2024)Insider Name:Keating Ashley M.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-472Price:$415.00
Filings by filing date
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Burwig Susan EOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-102Price:$403.00
-
Mar 14, 2024 (filed on Mar 18, 2024)Insider Name:Keating Ashley M.Ownership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-500Price:--
-
Mar 14, 2024 (filed on Mar 18, 2024)Insider Name:Keating Ashley M.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-250Price:$409.87
-
Mar 14, 2024 (filed on Mar 18, 2024)Insider Name:Keating Ashley M.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:500Price:$84.36
-
Mar 08, 2024 (filed on Mar 08, 2024)Insider Name:Troendle August J.Ownership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-25,000Price:$408.71
-
Mar 07, 2024 (filed on Mar 08, 2024)Insider Name:Troendle August J.Ownership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-75,000Price:$410.74
-
Mar 06, 2024 (filed on Mar 08, 2024)Insider Name:Troendle August J.Ownership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-100,000Price:$412.98
-
Mar 08, 2024 (filed on Mar 08, 2024)Insider Name:Medpace Investors, LLCOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-25,000Price:$408.71
-
Mar 07, 2024 (filed on Mar 08, 2024)Insider Name:Medpace Investors, LLCOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-75,000Price:$410.74
-
Mar 06, 2024 (filed on Mar 08, 2024)Insider Name:Medpace Investors, LLCOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-100,000Price:$412.98
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 5375 Medpace Way CINCINNATI OH 45227-1543 |
Tel: | N/A |
Website: | https://investor.medpace.com |
IR: | See website |
Key People | ||
August J. Troendle Chairman of the Board, Chief Executive Officer | Jesse J. Geiger President | Kevin M. Brady Chief Financial Officer, Treasurer |
Susan E. Burwig Executive Vice President - Operations | Stephen P. Ewald General Counsel, Corporate Secretary |
Business Overview |
Medpace Holdings, Inc. is a global provider of clinical research-based drug and medical device development services. The Company is focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. Its drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Its operations are based in North America, Europe, and Asia. |
Financial Overview |
For the fiscal year ended 31 December 2023, Medpace Holdings Inc revenues increased 29% to $1.89B. Net income applicable to common stockholders increased 15% to $282.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income was partially offset by Selling, general and administrative - B increase of 25% to $150.4M (expense). |
Employees: | 5,900 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $12,159M as of Dec 31, 2023 |
Annual revenue (TTM): | $1,886M as of Dec 31, 2023 |
EBITDA (TTM): | $363.15M as of Dec 31, 2023 |
Net annual income (TTM): | $282.62M as of Dec 31, 2023 |
Free cash flow (TTM): | $396.73M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 30,759,281 as of Feb 9, 2024 |
Index Membership: | S&P 400 Mid Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |